Examining the Rise of Early-onset Incidence Across Cancer Types
Researchers are exploring which cancer types have higher incidence in people under 50, what may be causing this rise of early-onset cancers.
Progress Against Cancer
Researchers are exploring which cancer types have higher incidence in people under 50, what may be causing this rise of early-onset cancers.
This month, the AACR's journals editors highlighted studies on U.S. cancer mortality hotspots, chemotherapy-induced hearing loss, and more.
Advances in cardio-oncology are redefining cancer care, shaping safer treatments to protecting patients’ hearts.
This post examines ultraprocessed foods and what current research shows about how they impact health and cancer risk.
Steroids at the start of immunotherapy can negatively affect response, and colorectal cancer may lead to sexual side effects in women.
New AI-driven models unveiled at the AACR Annual Meeting 2025 could revolutionize how we diagnose sarcomas in children.
Study found teclistamab-cqyv, an immunotherapy, led to responses in patients with high-risk, heavily pretreated multiple myeloma, including after prior BCMA therapy. Teclistamab-cqyv (Tecvayli), a type of immunotherapy, received accelerated approval from the U.S. Food...
‘Practice-changing’ research shows adding immunotherapy before and after surgery reduced recurrences for early-stage gastric cancer.
Uterine cancer diagnoses expected to climb in the next 25 years, and some disposable e-cigarettes emit more carcinogens than traditional cigarettes.
The FDA has approved sunvozertinib for certain patients with EGFR-mutated non-small Cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sunvozertinib (Zegfrovy) for the treatment of adult patients...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More